Jpmorgan Chase & CO Fusion Pharmaceuticals Inc. Transaction History

Jpmorgan Chase & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$7.9 - $21.32 $4.67 Million - $12.6 Million	591,709 Added 4216.55%	605,742 $12.9 Million
Q4 2023 Feb 12, 2024	BUY	$2.48 - $9.65 $34,796 - $135,399	14,031 Added 701550.0%	14,033 $134,000
Q3 2022 Nov 14, 2022	SELL	$2.0 - $3.56 $8,700 - $15,486	-4,350 Reduced 99.95%	2 $0
Q4 2021 Feb 10, 2022	BUY	$4.17 - $7.78 $5,675 - $10,588	1,361 Added 45.5%	4,352 $18,000
Q3 2021 Nov 12, 2021	BUY	$7.83 - $9.41 $23,419 - $28,145	2,991 New	2,991 $24,000

93K

1.4K

Ticker FUSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,390,500
Description
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order ...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.